CellAegis Announces First Patients Enrolled in U.S. Shield Pivotal Clinical Trial
Apr 10, 2018TORONTO, Canada, April 10, 2018 (GLOBE NEWSWIRE) – CellAegis Devices Inc. (“CellAegis” or the “Company”), a commercial-stage medical device company advancing innovative, non-invasive, safe and cost-effective solutions for acute and chronic cardiovascular conditions, today announced enrollment of the first patients in a U.S. clinical trial (“SHIELD”) of its autoRIC® device.
The autoRIC® device automatically delivers remote ischemic conditioning (“RIC”) to provide a non-invasive, cardio-protective therapy shown to reduce heart damage during heart attacks and certain cardiovascular procedures.